ECSP066925A - Derivados de piperidina como antagonistas del receptor de quimiocina - Google Patents
Derivados de piperidina como antagonistas del receptor de quimiocinaInfo
- Publication number
- ECSP066925A ECSP066925A EC2006006925A ECSP066925A ECSP066925A EC SP066925 A ECSP066925 A EC SP066925A EC 2006006925 A EC2006006925 A EC 2006006925A EC SP066925 A ECSP066925 A EC SP066925A EC SP066925 A ECSP066925 A EC SP066925A
- Authority
- EC
- Ecuador
- Prior art keywords
- receptor
- chemiokin
- antagonists
- piperidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente invención se relaciona con compuestos de Fórmula I: donde se definen sustituyentes variables, que modulan la actividad de o enlazan a los receptores de quimiocina tales como el CCR5. En algunos cuerpos, los compuestos de la invención son selectivos para CCR5. Los compuestos pueden ser usados, por ejemplo, para tratar enfermedades asociadas con la expresión del receptor de quiomicina o actividad como enfermedades inflamatorias, enfermedades inmunológicas e infecciones virales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56169704P | 2004-04-13 | 2004-04-13 | |
US57222104P | 2004-05-18 | 2004-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066925A true ECSP066925A (es) | 2006-12-20 |
Family
ID=35150660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006925A ECSP066925A (es) | 2004-04-13 | 2006-10-13 | Derivados de piperidina como antagonistas del receptor de quimiocina |
Country Status (20)
Country | Link |
---|---|
US (4) | US7678798B2 (es) |
EP (1) | EP1734966B1 (es) |
JP (2) | JP4948395B2 (es) |
KR (1) | KR101235090B1 (es) |
CN (1) | CN103012374B (es) |
AU (1) | AU2005234596B8 (es) |
BR (1) | BRPI0509803A (es) |
CA (1) | CA2562235C (es) |
CR (1) | CR8680A (es) |
EA (1) | EA015517B1 (es) |
EC (1) | ECSP066925A (es) |
ES (1) | ES2431524T3 (es) |
GE (1) | GEP20094680B (es) |
HU (1) | HU229709B1 (es) |
IL (1) | IL178622A (es) |
MX (1) | MXPA06011722A (es) |
NO (1) | NO337788B1 (es) |
NZ (1) | NZ550370A (es) |
RU (1) | RU2369604C2 (es) |
WO (1) | WO2005101838A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050024A2 (en) | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
JP4948395B2 (ja) * | 2004-04-13 | 2012-06-06 | インサイト・コーポレイション | ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体 |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2007143600A2 (en) | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
CN101293820B (zh) * | 2007-04-27 | 2012-10-10 | 天津药明康德新药开发有限公司 | 5-三氟甲基-1-茚酮的合成方法 |
WO2009012259A1 (en) * | 2007-07-16 | 2009-01-22 | Incyte Corporation | Pentafluorosulfanyl-substituted piperazinylpiperidine derivatives as chemokine receptor antagonists |
WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
KR101374409B1 (ko) * | 2011-10-17 | 2014-03-18 | 성균관대학교산학협력단 | 비유전성 항생제 내성 저해제 및 이의 용도 |
TW201706244A (zh) | 2015-05-07 | 2017-02-16 | 必治妥美雅史谷比公司 | 作為RORγ調節劑之三環碸類 |
EP3523279A1 (en) | 2016-10-10 | 2019-08-14 | Bristol-Myers Squibb Company | Tricyclic sulfones as ror gamma modulators |
WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
JPH10506608A (ja) | 1994-07-11 | 1998-06-30 | アセナ ニューロサイエンシーズ,インコーポレイテッド | 白血球接着のインヒビター |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
GB9522372D0 (en) | 1995-11-01 | 1996-01-03 | Merck Sharp & Dohme | Therapeutic agents |
US5704960A (en) | 1995-12-20 | 1998-01-06 | Corning, Inc. | Method of forming an optical fiber for reduced polarization effects in amplifiers |
GB9603741D0 (en) | 1996-02-22 | 1996-04-24 | Lin Mei | Treatment of water by electrolysis |
WO1998000412A1 (en) | 1996-07-01 | 1998-01-08 | Schering Corporation | Muscarinic antagonists |
US5935958A (en) | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
AU729415B2 (en) | 1996-07-12 | 2001-02-01 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
CA2291762A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
DE69820614T2 (de) | 1997-05-30 | 2004-09-30 | Celltech Therapeutics Ltd., Slough | Entzündungshemmende tyrosin-derivate |
AU8163398A (en) | 1997-06-23 | 1999-01-04 | Pharmacia & Upjohn Company | Inhibitors of alpha4beta1mediated cell adhesion |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
PL203116B1 (pl) * | 1999-05-04 | 2009-08-31 | Schering Corp | Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
US7825121B2 (en) * | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6635646B1 (en) * | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
CN1524527A (zh) | 1999-05-04 | 2004-09-01 | ���鹫˾ | 用作ccr5拮抗剂的哌啶衍生物 |
US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
ES2165274B1 (es) * | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
KR100613528B1 (ko) | 2001-03-29 | 2006-08-16 | 쉐링 코포레이션 | Ccr5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 |
ATE418542T1 (de) | 2001-03-29 | 2009-01-15 | Schering Corp | Als ccr5-antagonisten verwendbare aryloxim- piperazine |
AR036366A1 (es) | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
SE0103818D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
CA2467555A1 (en) | 2001-11-29 | 2003-08-14 | Schering Corporation | Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
AU2003207646C1 (en) | 2002-01-22 | 2008-09-18 | Vanderbilt University | Treating stress response with chemokine receptor CCR5 modulators |
EP1490352A1 (en) | 2002-03-29 | 2004-12-29 | Schering Corporation | Synthesis of piperidine and piperazine compounds as ccr5 antagonists |
WO2004002960A1 (en) | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
GB0223223D0 (en) | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
WO2004056772A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists |
MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
WO2004050024A2 (en) * | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
MXPA05006485A (es) * | 2002-12-17 | 2005-08-26 | Schering Corp | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno. |
PE20040769A1 (es) | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
JO2485B1 (en) | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
JO2696B1 (en) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
US7435736B2 (en) | 2002-12-23 | 2008-10-14 | Janssen Pharmaceutica, N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
ATE400568T1 (de) | 2002-12-23 | 2008-07-15 | Janssen Pharmaceutica Nv | Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten |
US20040235855A1 (en) * | 2003-03-31 | 2004-11-25 | Bharat Lagu | Phospholipase C inhibitors for use in treating inflammatory disorders |
ES2307025T3 (es) | 2003-06-10 | 2008-11-16 | Janssen Pharmaceutica Nv | Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor. |
WO2004113323A1 (en) | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
US7345042B2 (en) * | 2003-06-30 | 2008-03-18 | Schering Corporation | MCH antagonists for the treatment of obesity |
US7652142B2 (en) | 2003-11-03 | 2010-01-26 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
US7576089B2 (en) * | 2003-12-18 | 2009-08-18 | Incyte Corporation | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
JP4948395B2 (ja) * | 2004-04-13 | 2012-06-06 | インサイト・コーポレイション | ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体 |
GEP20084519B (en) * | 2004-05-11 | 2008-10-27 | Incyte Corp | 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors |
JP4116670B2 (ja) * | 2004-06-28 | 2008-07-09 | インサイト コーポレイション | ケモカイン受容体の調節剤としての3−アミノシクロペンタンカルボキサミド |
AU2005259983B2 (en) * | 2004-06-28 | 2011-07-28 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
CA2594114A1 (en) | 2005-01-06 | 2006-07-13 | Schering Corporation | Synthesis of ccr5 receptor antagonists |
CA2598489A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
EP1853583B1 (en) * | 2005-02-16 | 2011-09-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CA2598456A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
CA2598418A1 (en) | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
EP1856097B1 (en) | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
PE20061074A1 (es) | 2005-02-23 | 2006-11-08 | Schering Corp | Derivados de piperidinil piperidina como inhibidores de receptores de quimioquinas |
BRPI0609251A2 (pt) | 2005-02-23 | 2010-03-09 | Schering Corp | derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas |
MEP1008A (xx) * | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminociklopentankarboksamidi kao modulatori receptora hemokina |
TW200745087A (en) | 2006-02-24 | 2007-12-16 | Schering Corp | CCR5 antagonists useful for treating HIV |
US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
-
2005
- 2005-04-12 JP JP2007508441A patent/JP4948395B2/ja active Active
- 2005-04-12 ES ES05755295T patent/ES2431524T3/es active Active
- 2005-04-12 BR BRPI0509803-3A patent/BRPI0509803A/pt not_active Application Discontinuation
- 2005-04-12 MX MXPA06011722A patent/MXPA06011722A/es active IP Right Grant
- 2005-04-12 EA EA200601894A patent/EA015517B1/ru unknown
- 2005-04-12 GE GEAP20059702A patent/GEP20094680B/en unknown
- 2005-04-12 NZ NZ550370A patent/NZ550370A/en unknown
- 2005-04-12 HU HU0600858A patent/HU229709B1/hu unknown
- 2005-04-12 CA CA2562235A patent/CA2562235C/en active Active
- 2005-04-12 WO PCT/US2005/012265 patent/WO2005101838A2/en active Application Filing
- 2005-04-12 EP EP05755295.2A patent/EP1734966B1/en active Active
- 2005-04-12 KR KR1020067021380A patent/KR101235090B1/ko active IP Right Grant
- 2005-04-12 CN CN201210382208.5A patent/CN103012374B/zh active Active
- 2005-04-12 RU RU2006139946/04A patent/RU2369604C2/ru active
- 2005-04-12 US US11/104,041 patent/US7678798B2/en active Active
- 2005-04-12 AU AU2005234596A patent/AU2005234596B8/en active Active
-
2006
- 2006-10-09 CR CR8680A patent/CR8680A/es unknown
- 2006-10-13 EC EC2006006925A patent/ECSP066925A/es unknown
- 2006-10-15 IL IL178622A patent/IL178622A/en active IP Right Grant
- 2006-11-09 NO NO20065151A patent/NO337788B1/no unknown
-
2009
- 2009-04-13 US US12/422,517 patent/US8268826B2/en active Active
-
2011
- 2011-10-04 JP JP2011220378A patent/JP2012036210A/ja active Pending
-
2012
- 2012-08-01 US US13/564,434 patent/US8680104B2/en active Active
-
2014
- 2014-02-10 US US14/176,781 patent/US9067921B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066925A (es) | Derivados de piperidina como antagonistas del receptor de quimiocina | |
ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
NI201100084A (es) | Antagonistas del receptor de orexina de isonicotinamida. | |
BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
ECSP066991A (es) | 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
AR099023A1 (es) | Pirazolil-heteroarilamidas como agentes plaguicidas | |
ECSP12012218A (es) | Derivados de piperidin-4-il azetidina como inhibidores de jak1 | |
EA201170884A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов орексина | |
EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
DOP2010000234A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
SV2011003855A (es) | Heteroarilos sustituidos | |
GT200600042A (es) | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a | |
UY31830A (es) | Activadores de glucoquinasa | |
CY1119047T1 (el) | Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4 | |
NI201500050A (es) | Benzamidas | |
DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
ECSP099573A (es) | Derivados heterocíclicos como receptores muscarínicos m3 | |
CO6470792A2 (es) | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida | |
SV2010003747A (es) | Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia | |
UY31717A1 (es) | (pirazolilcarbonil) imidazolidinonas sustituidas y su uso |